Robert E. Landry

Robert E. Landry

DirectoratRegeneron Pharmaceuticals· In proxies 2021–2025

Pay in FY2024-85% from the year before · Regeneron Pharmaceuticals stock -18.9% the same year

Robert E. Landry was paid $282.0K in FY2024 (Dec), down 85%. Regeneron Pharmaceuticals stock fell 18.9% that year.

Pay$100 in the stock at the end of FY20 → $147
Pay is from the Summary Compensation Table of each Regeneron Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. CytokineticsPublic company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  2. ZymeworksPublic company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  3. Regeneron PharmaceuticalsPublic company · 5 yr
    • Former Executive Vice President, Finance and Chief Financial Officer2021 – Present · 5 yrStock in role +66%

Roles come from the proxy statements of each company.

Boards2

  • ZymeworksDirector · 0 yr on the boardIndependentAudit, Compensation—Paid as an executive
  • CytokineticsDirector · -1 yr on the boardIndependentAudit—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?